Literature DB >> 2885917

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

P P Di Fiore, J H Pierce, M H Kraus, O Segatto, C R King, S A Aaronson.   

Abstract

A wide variety of human tumors contain an amplified or overexpressed erbB-2 gene, which encodes a growth factor receptor-like protein. When erbB-2 complementary DNA was expressed in NIH/3T3 cells under the control of the SV40 promoter, the gene lacked transforming activity despite expression of detectable levels of the erbB-2 protein. A further five- to tenfold increase in its expression under influence of the long terminal repeat of Moloney murine leukemia virus was associated with activation of erbB-2 as a potent oncogene. The high levels of the erbB-2 product associated with malignant transformation of NIH/3T3 cells were observed in human mammary tumor cells that overexpressed this gene. These findings demonstrate a new mechanism for acquisition of oncogenic properties by genes encoding growth factor receptor-like proteins and provide a functional basis for the role of their overexpression in the development of human malignancies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885917     DOI: 10.1126/science.2885917

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  256 in total

1.  Signalling-competent truncated forms of ErbB2 in breast cancer cells: differential regulation by protein kinase C and phosphatidylinositol 3-kinase.

Authors:  A Esparís-Ogando; E Díaz-Rodríguez; A Pandiella
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Positive and negative regulation of endogenous genes by designed transcription factors.

Authors:  R R Beerli; B Dreier; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

Review 3.  Mediterranean diet, olive oil and cancer.

Authors:  Ramón Colomer; Javier A Menéndez
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

4.  Basolateral targeting of ERBB2 is dependent on a novel bipartite juxtamembrane sorting signal but independent of the C-terminal ERBIN-binding domain.

Authors:  Christian Dillon; Anna Creer; Karen Kerr; Angelika Kümin; Clive Dickson
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

5.  MyoD induces growth arrest independent of differentiation in normal and transformed cells.

Authors:  M Crescenzi; T P Fleming; A B Lassar; H Weintraub; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

Review 6.  Application of molecular cytogenetic techniques to the evaluation of renal parenchymal tumors.

Authors:  G Kovacs
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 7.  The ERBB network: at last, cancer therapy meets systems biology.

Authors:  Yosef Yarden; Gur Pines
Journal:  Nat Rev Cancer       Date:  2012-07-12       Impact factor: 60.716

Review 8.  Roles for growth factors in cancer progression.

Authors:  Esther Witsch; Michael Sela; Yosef Yarden
Journal:  Physiology (Bethesda)       Date:  2010-04

9.  Immunohistochemical evaluation of erbB-2 and p53 protein expression in benign and atypical human meningiomas.

Authors:  B S Chozick; D L Benzil; E G Stopa; J C Pezzullo; N W Knuckey; M H Epstein; S D Finkelstein; P W Finch
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

10.  eps15, a novel tyrosine kinase substrate, exhibits transforming activity.

Authors:  F Fazioli; L Minichiello; B Matoskova; W T Wong; P P Di Fiore
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.